[Update in interstitial lung disease 2021].

The significant scientific advances about interstitial lung disease from November 2020 to October 2021 which were published in the Chinese and international journals were systematically reviewed in this paper. The year 2021 brought advances in our understanding of the real-world adoption of the antifibrotic medications pirfenidone and nintedanib for US idiopathic pulmonary fibrosis patients, the European statement on the diagnosis and evaluation and treatment of pulmonary fibrosis, the CHEST guideline on the diagnosis and evaluation of hypersensitivity pneumonitis, Chinese expert viewpoints on the progressive fibrosing interstitial lung disease, and international updates on the diagnosis and management of connective tissue disease-associated interstitial lung diseases.